Skip to main content
    E

    Exagen Inc (XGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $3.77
    -0.36 (-8.72%)

    Market Cap: $105.37M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Exagen Inc (XGN) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Exagen (XGN) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Exagen reported EPS of -$0.25, below the -$0.19 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    69%(20/29)
    Avg Surprise
    -1.71%

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.19
    Range-$0.21 - -$0.17
    9 analysts
    Revenue Consensus
    $18.25M
    Range$16.76M - $19.43M
    9 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.17
    Range-$0.19 - -$0.14
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.15-11.1%
    60d ago-$0.16-7.5%
    30d ago-$0.16-7.5%
    7d ago-$0.16-7.5%
    Current-$0.17
    Revenue Consensus
    $18.42M
    Range$17.80M - $18.90M
    5 analysts

    Next Report

    XGN has an expected report date of Mar 8, 2027.

    XGN Earnings Call

    The latest XGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, XGN beat 20, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $18.42M, up 6.8% from $17.24M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.25-$0.19N/A-31.58%MissN/A20 up, 1 downNov 10, 2026$18.42M
    Jun 30, 2026-$0.13-$0.19N/A+31.58%BeatN/A1N/AAug 4, 2026$19.94M
    Mar 31, 2026-$0.20-$0.25-$0.25 - -$0.25+20.00%BeatN/A21 up, 2 downMay 11, 2026$17.31M
    Dec 31, 2025-$0.27-$0.18-$0.23 - -$0.17-48.80%MissN/A60 up, 3 downMar 10, 2026$16.63M
    Sep 30, 2025-$0.31-$0.16-$0.18 - -$0.14-93.75%MissN/A40 up, 1 downNov 4, 2025$17.24M
    Jun 30, 2025-$0.18-$0.15-$0.18 - -$0.12-20.00%MissN/A50 up, 3 downJul 29, 2025$17.20M
    Mar 31, 2025-$0.20-$0.21-$0.23 - -$0.19+4.76%BeatN/A32 up, 1 downMay 5, 2025$15.50M
    Dec 31, 2024-$0.20-$0.24-$0.30 - -$0.10+16.67%BeatN/A51 up, 1 downMar 11, 2025$13.65M
    Sep 30, 2024-$0.28-$0.28-$0.32 - -$0.260.00%In lineN/A60 up, 0 downNov 12, 2024$12.51M
    Jun 30, 2024-$0.16-$0.35-$0.37 - -$0.29+54.29%BeatN/A61 up, 0 downAug 5, 2024$15.06M
    Mar 31, 2024-$0.19-$0.35-$0.40 - -$0.32+45.71%BeatN/A60 up, 0 downMay 13, 2024$14.41M
    Dec 31, 2023-$0.31-$0.43-$0.48 - -$0.39+27.91%BeatN/A60 up, 0 downMar 18, 2024$13.77M
    Sep 30, 2023-$0.31-$0.49-$0.50 - -$0.36+36.73%BeatN/A60 up, 0 downNov 13, 2023$13.42M
    Jun 30, 2023-$0.28-$0.49-$0.53 - -$0.47+42.86%BeatN/A60 up, 0 downAug 7, 2023$14.14M
    Mar 31, 2023-$0.44-$0.56-$0.61 - -$0.49+21.43%BeatN/A60 up, 0 downMay 15, 2023$11.23M
    Dec 31, 2022-$0.83-$0.78-$0.81 - -$0.71-6.41%MissN/A60 up, 0 downMar 20, 2023$12.84M
    Sep 30, 2022-$0.47-$0.76-$0.80 - -$0.58+38.16%BeatN/A61 up, 0 downNov 14, 2022$14.73M
    Jun 30, 2022-$0.78-$0.57N/A-36.84%MissN/AN/A0 up, 0 downAug 4, 2022$7.61M
    Mar 31, 2022-$0.60-$0.61-$0.64 - -$0.55+1.64%BeatN/A60 up, 0 downMay 11, 2022$10.39M
    Dec 31, 2021-$0.42-$0.50-$0.61 - -$0.35+16.00%BeatN/A60 up, 0 downMar 22, 2022$12.69M
    Sep 30, 2021-$0.42-$0.47-$0.56 - -$0.39+10.64%BeatN/A6N/ANov 10, 2021$12.25M
    Jun 30, 2021-$0.38-$0.44-$0.59 - -$0.37+13.64%BeatN/A6N/AAug 9, 2021$12.77M
    Mar 31, 2021-$0.48-$0.48-$0.55 - -$0.410.00%In lineN/A6N/AMay 11, 2021$10.59M
    Dec 31, 2020-$0.27-$0.41-$0.45 - -$0.33+34.15%BeatN/A5N/AMar 16, 2021$12.67M
    Sep 30, 2020-$0.34-$0.47-$0.54 - -$0.45+27.66%BeatN/A4N/ANov 10, 2020$10.78M
    Jun 30, 2020-$0.27-$0.79-$0.82 - -$0.68+65.82%BeatN/A3N/AJul 28, 2020$8.95M
    Mar 31, 2020-$0.44-$0.56-$0.63 - -$0.34+21.43%BeatN/A3N/AMay 11, 2020$9.58M
    Dec 31, 2019-$0.27-$0.37-$0.40 - -$0.33+27.03%BeatN/A3N/AMar 25, 2020$10.21M
    Sep 30, 2019-$11.29-$2.40-$4.22 - -$0.58-370.42%MissN/A2N/ANov 12, 2019$10.44M
    Jun 30, 2019-$1.60N/AN/AN/AN/AN/AN/AN/ASep 20, 2019$10.47M
    Mar 31, 2015-$0.27N/AN/AN/AN/AN/AN/AN/AJun 29, 2015$4.37M
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.96, after -$0.83 the year before. It was -$13.43 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.96N/A
    Dec 31, 2024-$0.83N/A
    Dec 31, 2023-$1.34N/A
    Dec 31, 2022-$2.68N/A
    Dec 31, 2021-$1.70N/A
    Dec 31, 2020-$1.32N/A
    Dec 31, 2019-$13.43N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,23011
    2026Q2Jun 30, 20266,17110
    2026Q1Mar 31, 20266,3449
    2025Q3Sep 30, 20258,02411
    2025Q2Jun 30, 20255,7868
    2025Q1Mar 31, 20257,3859
    2024Q4Dec 31, 20247,24110
    2024Q3Sep 30, 20247,6139

    2026Q3 Earnings Call

    Opening remarks

    Tina Jacobsen Head of Investor Relations Thanks, operator. Good morning, and thank you for joining us to discuss Exagen's financial results for the quarter ended September 30, 2026. Today, I'm joined by John Aballi, our President and Chief Executive Officer, and Jeff Black, our Chief Financial Officer. The recording of this call, the press release announcing our financial results, and the slide presentation can be accessed on our website at www.exagen.com. Today's call will include forward-looking statements. We encourage you to review the statements contained in today's press release and the risks and uncertainties described in our SEC filings, which identify certain factors that may cause the company's actual events, performance, and results to differ materially from those contained in the forward-looking statements made on today's call. We also will discuss non-GAAP financial measures on this call. Descriptions of these non-GAAP financial measures and the reconciliations of GAAP to non-GAAP financial measures are included in today's press release. And now I will turn the call over to John Aballi. John?

    John Aballi President and Chief Executive Officer Good morning, everyone, and thank you for joining us. The third quarter extended what is fast becoming a record year for Exagen, with execution toward our vision increasingly evident in the results. I'll get right into the details. This morning, we reported third quarter revenue of $18.4 million, the best third quarter in company history. Year-to-date, revenue has grown more than 11%, which has contributed to an adjusted EBITDA improvement of over 30%. We grew both volume and price compared to last year. Trailing 12-month ASP reached a new record of $451, marking our 14th consecutive quarter of improvement. That speaks to the durability of our growth, and we're confidently reiterating full-year revenue guidance of $72 million to $75 million. During the quarter, we utilized our ATM facility to strengthen the balance sheet and opportunistically brought in high-caliber investors as we continue to build and shape the company for the long term. We're really pleased to have their support. As always, our mission is at the heart of everything we do. Autoimmune disease is diagnosed too late and too inconsistently, and it's the patients who suffer. This is why Exagen exists, and we are singularly focused on building a unique platform to bring clarity to these complex diseases. I spent a good amount of time in the field with customers over the last few months, and the conversations I had reinforced the critical nature of our work and the strategic path we're taking. I visited with customers here in Southern California, Louisiana, and New York to discuss our offerings, how we can better support their practices, and to preview new products that will address important diagnostic challenges.

    Frequently Asked Questions About XGN

    When is Exagen's next earnings date?

    Exagen's next earnings report is expected for Mar 8, 2027.

    Did XGN beat earnings estimates last quarter?

    No. Exagen reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.19 estimate by 31.58%.

    What EPS do analysts expect from XGN next quarter?

    The consensus EPS estimate for Exagen for the quarter ending Dec 31, 2026 is -$0.19 from 9 analysts, with estimates from -$0.21 to -$0.17.

    How often does XGN beat earnings estimates?

    Exagen beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -15.14%.